Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Recruiting · NCT06121180 · Registry updated 2025-12-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Recruiting | Phase 2 | 2025-12-04 | NCT06121180 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genzyme, a Sanofi Company | 22 |
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
| Regeneron Pharmaceuticals | 238 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | United States | 523 |
| Northwell Health Center for Advanced Medicine | New Hyde Park | United States | 1 |
| The Angeles Clinic and Research Institute | Los Angeles | United States | 16 |
| University of Chicago Medical Center | Chicago | United States | 152 |